CEO Brandon Robinson on Horizon Aircraft’s (HOVR) Commercial eVTOL Advantages

About this episode

Brandon Robinson discusses Horizon Aircraft's innovative approach to eVTOL technology and its market potential.

In our exclusive interview, Brandon Robinson, Co-Founder, CEO, and Director of New Horizon Aircraft (Nasdaq: HOVR) breaks down why Horizon is taking a different path in advanced air mobility and why investors are starting to pay attention.Horizon’s Cavorite X7 is designed to combine vertical takeoff capability with the speed, range, and economics of a conventional aircraft. The company is targeting performance of about 250 mph, 500-mile range, and up to 1,500 lbs of payload, with operating costs estimated at about $0.97 per seat mile versus roughly $4 to $6 for comparable helicopters. The company has also completed large-scale prototype testing, including vertical takeoff, transition, and forward flight, with a full-scale aircraft currently under construction.For investors, the story is about more than innovation. Horizon is targeting a large installed base of roughly 70,000 helicopters globally, pursuing a capital-efficient OEM model, and positioning itself in high-value mission-critical markets where infrastructure-light aircraft can solve real operational problems. 👉 New Horizon Aircraft is a client of RedChip. Visit https://www.HOVRinfo.com to learn more and sign up for news…

People in this episode

Guest: Brandon Robinson

Topics covered

• eVTOL
• advanced air mobility
• aviation innovation
• investment opportunities
• helicopter market
• aerospace technology

Keywords

• HOVR
• Horizon Aircraft
• eVTOL
• aviation stocks
• small cap stocks
• growth stocks
• investing
• air mobility
• aerospace

Sponsors

RedChip Companies

Mentioned in this episode

Organizations: New Horizon Aircraft, Nasdaq

Products: Cavorite X7

Places: Horizon Aircraft

More episodes of Small Stocks, Big Money

• CEO Lavell Malloy on Brag House's (Nasdaq: TBH) Blockchain Sports Platform & Athlete Tokenization · June 9, 2026 · 6 min
• CEO James Foster on Virax Biolabs' (VRAX) Long COVID Diagnostic & US Market Entry · May 25, 2026 · 9 min
• Jeremy Schwartz CIO of WisdomTree ($WT): $165B AUM, Mega Trends & Why WT Is a Secular Growth Stock · May 20, 2026 · 9 min
• First Phosphate (FRSPF) CEO on Agnico's $94M Bet Leaves Only 2 Independents Standing · May 12, 2026 · 8 min
• Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data · May 11, 2026 · 9 min
• First Phosphate (FRSPF) CEO on $16.7M Non-Dilutive Funding, LFP Batteries, and Why FRSPF Stands Out · April 21, 2026 · 8 min